Antifibrotic Pirfenidone in Patients With Progressive Pulmonary Fibrosis
Is the antifibrotic pirfenidone an effective and safe therapy for individuals with progressive pulmonary fibrosis?
Pulmonary Fibrosis
Progressive Fibrosing Interstitial Lung Disease: Prevalence and Characteristics
What characterizes the progressive fibrosing ILD phenotype, and what baseline factors associated with this phenotype may help guide clinical decision making?
Malignancy Risk of Mycophenolate Mofetil and Azathioprine in Fibrotic ILD
Are patients with fibrotic interstitial lung disease at risk of malignancy when treated with the immunomodulatory drugs MMF and AZA?
Can BMI and Weight Loss Predict Mortality in Fibrotic Interstitial Lung Disease?
Researchers assessed whether BMI and weight loss are reliable prognostic indicators in patients with fibrotic interstitial lung disease.
Pulmonary Rehab for Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis
A review of 21 studies evaluated the long-term outcomes associated with pulmonary rehabilitation for patients with pulmonary fibrosis, including ILD.
Predictors of Disease Progression and Mortality in Non-IPF Fibrosing ILD
The researchers sought to identify predictors of disease progression and mortality in non-IPF fILD using criteria from the INBUILD, RELIEF, and uILD trials.
Switching Antifibrotic Agents May Improve Outcomes in Idiopathic Pulmonary Fibrosis
Because the 2 antifibrotics in use — pirfenidone and nintedanib — have differing mechanisms of action, when one is ineffective the other may provide benefit, thus improving survival.
Time to Death, Lung Transplant Not Reduced With Co-Trimoxazole in Moderate, Severe IPF
Trimethoprim-sulfamethoxazole therapy did not reduce time to death, lung transplant, or hospitalization in patients with moderate or severe idiopathic pulmonary fibrosis.
Review Provides Insights Into Pulmonary Hypertension Among Patients With Pulmonary Fibrosis
The understanding of the role of specific molecular mechanisms causing pulmonary hypertension in people with pulmonary fibrosis is growing but still in its infancy.
Combination Metformin and Low-Dose Nintedanib Reduces Pulmonary Fibrosis
Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.
- Loading...
Loading...
Next post in CHEST 2019
Loading... 
Loading...